HK1155943A1 - Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders - Google Patents

Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders

Info

Publication number
HK1155943A1
HK1155943A1 HK11110041.5A HK11110041A HK1155943A1 HK 1155943 A1 HK1155943 A1 HK 1155943A1 HK 11110041 A HK11110041 A HK 11110041A HK 1155943 A1 HK1155943 A1 HK 1155943A1
Authority
HK
Hong Kong
Prior art keywords
combination
treatment
pharmaceutical composition
cognitive disorders
composition containing
Prior art date
Application number
HK11110041.5A
Other languages
English (en)
Inventor
Olivier Bergis
Philippe Pichat
Alexandre Urani
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HK1155943A1 publication Critical patent/HK1155943A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK11110041.5A 2008-06-02 2011-09-23 Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders HK1155943A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0802996A FR2931677B1 (fr) 2008-06-02 2008-06-02 Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
PCT/FR2009/051041 WO2009156680A2 (fr) 2008-06-02 2009-06-02 Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition pharmaceutique la contenant et son utilisation dans le traitement des troubles cognitifs

Publications (1)

Publication Number Publication Date
HK1155943A1 true HK1155943A1 (en) 2012-06-01

Family

ID=40229706

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11110041.5A HK1155943A1 (en) 2008-06-02 2011-09-23 Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders

Country Status (15)

Country Link
US (1) US20110136791A1 (xx)
EP (1) EP2293790A2 (xx)
JP (1) JP2011522017A (xx)
KR (1) KR20110021946A (xx)
CN (1) CN102046164B (xx)
AU (1) AU2009264016B2 (xx)
BR (1) BRPI0913236A2 (xx)
CA (1) CA2726291A1 (xx)
FR (1) FR2931677B1 (xx)
HK (1) HK1155943A1 (xx)
IL (1) IL209601A0 (xx)
MX (1) MX2010013241A (xx)
RU (1) RU2493851C2 (xx)
SG (1) SG191623A1 (xx)
WO (1) WO2009156680A2 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
MX2013003344A (es) 2010-09-23 2013-06-28 Abbvie Inc Monohidrato de un derivado de azaadamantano.
US9829326B2 (en) 2012-04-14 2017-11-28 Audi Ag Method, system and vehicle for conducting group travel
CN103333163A (zh) * 2013-07-09 2013-10-02 广州中医药大学 一种苯并呋喃类衍生物及其制备方法和应用
ES2822562T3 (es) * 2014-10-03 2021-05-04 Lachesis Biosciences Ltd Composiciones intranasales para el tratamiento de enfermedades y trastornos neurológicos y degenerativos
RU2624978C2 (ru) * 2015-07-27 2017-07-11 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ лечения умеренного когнитивного снижения

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141762A0 (en) * 1998-10-01 2002-03-10 Novartis Ag New oral formulations
FR2791678B1 (fr) * 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
US20010036949A1 (en) * 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
EP1231212B1 (en) * 2001-02-06 2006-12-20 Pfizer Products Inc. Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders
DK1381384T3 (da) * 2001-04-24 2011-07-25 Merck Patent Gmbh Kombinationsterapi under anvendelse af anti-angiogene midler og TNFalfa
TW200418446A (en) * 2002-10-24 2004-10-01 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
BR0317110A (pt) * 2002-12-11 2005-10-25 Pharmacia & Upjohn Co Llc Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos
EP1641454B1 (en) * 2003-06-27 2008-10-01 Pfizer Products Inc. Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
JP2007519733A (ja) * 2004-01-26 2007-07-19 コーテックス ファーマシューティカルズ インコーポレーティッド アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法
TW200533371A (en) * 2004-04-15 2005-10-16 Dainippon Pharmaceutical Co Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
US7632831B2 (en) * 2004-05-07 2009-12-15 Memory Pharmaceuticals Corporation 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
JP2009526776A (ja) * 2006-02-14 2009-07-23 ノイロサーチ アクティーゼルスカブ 新規なジアザビシクロアルカン誘導体及びその医療上の使用
US20100234349A1 (en) * 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
KR101122469B1 (ko) * 2007-04-02 2012-07-12 파킨슨즈 인스티튜트 처치 치료의 부작용을 감소시키기 위한 방법 및 조성물
MY152486A (en) * 2008-03-19 2014-10-15 Janssen Pharmaceutica Nv Trisubstituted 1,2,4 - triazoles as nicotinic acetylcholine receptor modulators
CN102015655A (zh) * 2008-05-09 2011-04-13 詹森药业有限公司 作为乙酰胆碱受体调节剂的三取代吡唑类

Also Published As

Publication number Publication date
JP2011522017A (ja) 2011-07-28
CN102046164A (zh) 2011-05-04
RU2010154417A (ru) 2012-07-20
MX2010013241A (es) 2011-01-21
AU2009264016B2 (en) 2014-09-11
FR2931677B1 (fr) 2010-08-20
BRPI0913236A2 (pt) 2016-01-19
KR20110021946A (ko) 2011-03-04
RU2493851C2 (ru) 2013-09-27
AU2009264016A1 (en) 2009-12-30
EP2293790A2 (fr) 2011-03-16
IL209601A0 (en) 2011-02-28
CN102046164B (zh) 2013-02-20
CA2726291A1 (fr) 2009-12-30
WO2009156680A2 (fr) 2009-12-30
FR2931677A1 (fr) 2009-12-04
WO2009156680A3 (fr) 2010-04-22
SG191623A1 (en) 2013-07-31
US20110136791A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
PH12017500930A1 (en) Hsp90 inhibitor combinations
HK1155943A1 (en) Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders
HK1220631A1 (zh) 用於遞送治療劑的陰離子核心組合物以及製備和使用所述組合物的方法
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
EP2023926A4 (en) PYRIDONECARBOXAMIDE DERIVATIVES USEFUL FOR TREATING HYPERPROLIFERATIVE AND ANGIOGENESIS RELATED DISORDERS
MX354402B (es) Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
MX2011011950A (es) Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
UA98839C2 (xx) N,n-дизаміщені аміноалкілбіфенільні антагоністи рецепторів простагландину d2$n,n-дизамещенные аминоалкилбифенильные антагонисты рецепторов простагландина d2
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
WO2010083385A3 (en) Compounds for reducing drug resistance and uses thereof
EP1740172A4 (en) ACETYLCHOLINESTERASE INHIBITORS AND N-METHYL-D-ASPARTATE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DISORDER
MX2009006812A (es) Moduladores del receptor c3a y metodos de uso de los mismos.
MX2011010782A (es) Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos.
IN2012DN02471A (xx)
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
IL206562A0 (en) Novel catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition
HK1162502A1 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3
IL200570A0 (en) Combination therapy, composition and methods for the treatment of cardiovascular disorders
IL182738A0 (en) Enantiomers of 3-heteroaryl-8h-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors
MX2010001187A (es) Moduladores del receptor ccr9 y metodos para su uso.
GB2459598A (en) Heterodimers and methods of using them
MX2009004113A (es) Composicion que comprende un antagonista del receptor de neuroquinina-1 y un inhibidor selectivo de la recaptacion de serotonina para el tratamiento de tinnitus y perdida auditiva.
TN2011000214A1 (en) Combination of hsp90 and herceptin inhibitors
GEP20115158B (en) Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170602